[CAP7 (1-16)]2, (sC18)2

General Information


DRACP ID  DRACP03734

Peptide Name   [CAP7 (1-16)]2, (sC18)2

Sequence  GLRKRLRKFRNKIKEK,GLRKRLRKFRNKIKEK

Sequence Length  33

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  Mix



Physicochemical Information


Formula  C184H332N68O38

Absent amino acids  ACDHMPQSTVWY

Common amino acids  K

Mass  467602

Pl  12.75

Basic residues  18

Acidic residues  2

Hydrophobic residues  8

Net charge  16

Boman Index  -16440

Hydrophobicity  -181.82

Aliphatic Index  70.91

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 23209513

Title  Dimerization of a cell-penetrating peptide leads to enhanced cellular uptake and drug delivery

Doi Not available

Year  2012

Literature 2

Pubmed ID 27860402

Title  Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity

Doi Not available

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  12024

DRACP is developed by Dr.Zheng's team.